Citations

Clear

16281 citation(s) found for "Li, David".

Sleeping Beauty mutagenesis identifies BACH2 and other regulators of CD8 + T-cell exhaustion, persistence in vivo, and CAR-T cell f
Lee, Chungchi , Larsson, Alex T, Jubenville, Tyler A, Hudson, Wendy A, Seeman, Zach J, Stewart, Carli M. , Tsai, Alexander K. , Burrack, Adam, Kimball, Brooke L, Siegler, Elizabeth L, Vianzon, Vianca , Nolan, Erin E, Yang, Yu-Ling, Stehn, Christopher M, Gohl, Daryl M, Donovan, Margaret, Temiz, Nuri A, Popescu, Flavia E, Warming, Søren, Seshagiri, Somasekar, You, Yun, Riordan, Jesse D, Dupuy, Adam, Moriarity, Branden, Stromnes, Ingunn M. , Kenderian, Saad, Largaespada, David A. , Gohl, Daryl M. , Lee, Chang-Jung , Stewart, Carli , Vianzon, Vianca V , Rogers, Laura M , Stromnes, Ingunn M , Largaespada, David A. , Tsai, Alexander K , Larsson, Alex T. , Jubenville, Tyler , Hudson, Wendy A. , Seeman, Zachary J. , Burrack, Adam L. , Kimball, Brooke , Siegler, Elizabeth L. , Nolan, Erin E. , Stehn, Christopher M. , Donovan, Margaret , Temiz, Nuri A. , Popescu, Flavia E., Seshagiri, Somasekar , Riordan, Jesse D. , Dupuy, Adam J. , Moriarity, Branden S. , Rogers, Laura M. , Kenderian, Saad

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 15, 2026 | Volume: 14 | Issue: 7 | Pages: e013536

10.1136/jitc-2025-013536 | PMID 42457339 Get It

Background Genes that enhance T-cell function represent promising targets for improving engineered T-cell therapies for cancer. While extensive CRISPR knockout screens have identified key genes enhancing T-cell persistence, employing Sleeping Beauty ( SB ) insertional mutagenesis, which induces both gain-of-function (GOF) and loss-of-function (LOF) mutations via the generation of fusion transcripts with endogenous genes, may uncover additional critical factors that previous approaches have overlooked. Methods We developed transgenic mice carrying D oxycycline (Dox)- i nducible SB mutag e nesis s y stem (DiSBey) in primary T cells. Using DiSBey, we conducted screens for genetic alterations enhancing T-cell persistence under chronic antigen exposure. Specifically, CD8 + T cells from Dox-fed DiSBey mice were subjected to repeated anti-CD3 stimulation over 18 days to mimic chronic antigenic stimulation. We then identified SB transposon genomic insertion sites and corresponding fusion transcripts from the persistent DiSBey CD8 + T cells using enhanced-specificity tagmentation sequencing and RNA sequencing, respectively. Results Under chronic stimulation, SB -mutagenized CD8 + T cells exhibited improved persistence and reduced terminal exhaustion phenotype. Across six independent screens, we identified 38 genes that were recurrently targeted by the SB transposon T2/Onc2 and differentially expressed under chronic anti-CD3 stimulation. T2/Onc2 insertions into Bach2 and Elmo1 were recurrently identified at the genomic level and were associated with altered nascent transcript expression. Bach2 , known as a key regulator of T-cell memory formation and resistance to chronic viral infection-induced exhaustion but less characterized in engineered T cells for cancer therapy, was found to counteract exhaustion in vitro and enhance in vivo tumor persistence in the B16-Ova tumor model. Further, we showed that ectopic Bach2 expression levels influence engineered T-cell differentiation lineage, as low Bach2 overexpression retained more functional progenitor exhausted T cells and exhibited improved therapeutic efficacy. Finally, in human CART19-28ζ cells, BACH2 overexpression enhanced cytotoxicity and tumor control following chronic cancer stimulation. Conclusions Controllable SB mutagenesis using DiSBey mice provides a novel platform for functional screening of genes that improve T-cell phenotypes important for their use as therapies. Our findings highlight a dose-dependent role of BACH2 in enhancing the function of engineered T cells under conditions of chronic antigenic stimulation.
Minor stroke, major stakes: impact of procedure duration on thrombectomy outcomes in minor stroke
Kasem, Rahim Abo, Baba, Bachar El, Ma, Tianwen, Zelmanovich, Rebecca, Pabaney, Aqueel, Khelo, Roy Raheb, Giraudo, Francesca, Chandler, Katherine, Elawady, Sameh Samir, Chalhoub, Reda, Levitt, Michael R., Mascitelli, Justin, Cawley, Charles Michael, Akbik, Feras, Chisango, Zvipo, Wolfe, Stacey Quintero, Kim, Joon-Tae, Jabbour, Pascal, Yoshimura, Shinichi, Maier, Ilko, Ogilvy, Christopher S., Ezzeldin, Mohamad, Psychogios, Marios-Nikos, Siddiqui, Fazeel, Navia, Pedro, Goyal, Nitin, Arthur, Adam S., Romano, Daniele G., Fragata, Isabel, Daglioglu, Ergun, Altschul, David, Park, Min S., Crosa, Roberto, Brinjikji, Waleed, Moss, Mark, Dye, Justin, Alaraj, Ali, Kan, Peter, Limaye, Kaustubh, Mokin, Maxim, Starke, Robert M., Spiotta, Alejandro M., Grossberg, Jonathan A , Alawieh, Ali M., Kasem, Rahim Abo , Baba, Bachar El , Ma, Tianwen , Zelmanovich, Rebecca , Pabaney, Aqueel, Khelo, Roy Raheb , Giraudo, Francesca, Chacón-Aponte, Ariana Alejandra , Chandler, Katherine , Elawady, Sameh Samir , Howard, Brian M , Levitt, Michael R. , Grandhi, Ramesh , Mascitelli, Justin R , Cawley, Charles Michael, Akbik, Feras , Chisango, Zvipo Mutsa , Wolfe, Stacey Q , Kim, Joon‐Tae , Jabbour, Pascal , Maier, Ilko , Ogilvy, Christopher S. , Ezzeldin, Mohamad , Psychogios, Marios‐Nikos , Navía, Pedro , Goyal, Nitin , Arthur, Adam S., Romano, Daniele Giuseppe , Fragata, Isabel , Dağlıoğlu, Ergün , Altschul, David , Crosa, Roberto , Brinjikji, Waleed , Moss, Mark, Dye, Justin , Alaraj, Ali , Limaye, Kaustubh , Mokin, Maxim , Starke, Robert M. , Spiotta, Alejandro M , Alawieh, Ali

Mayo Clinic

Journal of Neurosurgery | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-12

10.3171/2026.2.jns252558 | PMID 42468039 Get It

OBJECTIVE Endovascular thrombectomy (EVT) for acute large-vessel occlusion stroke is well established, yet its role in patients presenting with minor stroke symptoms (National Institutes of Health Stroke Scale [NIHSS] score < 6) remains unclear. Prior studies have not accounted for intraprocedural factors that may influence outcomes in this subgroup. METHODS The authors analyzed 5693 patients from the STAR (Stroke and Thrombectomy and Aneurysm Registry), including 398 with low NIHSS scores, to evaluate the association between procedure time (PT) and outcomes. Among patients with low NIHSS scores, propensity score matching was used to compare outcomes between those with PT ≤ 35 versus > 35 minutes, a cutoff defined using receiver operating characteristic curve analysis. The authors performed a meta-analysis of studies reporting best medical management (BMM) outcomes in patients with low NIHSS scores. To compare these with EVT-treated patients, a matched BMM comparator cohort using stratification on pooled baseline characteristics was constructed. Outcomes included 90-day functional independence (modified Rankin Scale [mRS] scores 0–2), intracranial hemorrhage, and mortality. RESULTS PT had a stronger negative effect on outcomes in patients with low NIHSS scores compared with those with high scores, with a steeper decline in functional independence per minute of PT (slope: –0.45% vs –0.21%; p = 0.03 for interaction). Among patients with low scores, PT ≤ 35 minutes was associated with higher 90-day functional independence compared with the propensity score–matching cohort with PT > 35 minutes (82.6% vs 59.0%, p < 0.001). When benchmarked against BMM (75.2% mRS scores 0–2), patients undergoing EVT within 35 minutes had superior outcomes (85.1%, p = 0.047). In contrast, EVT with PT > 35 minutes resulted in worse outcomes than BMM (mRS scores 0–2: 59.8%, p = 0.008). The number needed to treat for PT ≤ 35 minutes was 10, whereas PT > 35 minutes yielded a number needed to harm of 6. CONCLUSIONS PT critically modulates the benefit of EVT in minor stroke. While efficient EVT yields better outcomes than BMM, prolonged procedures are associated with harm. These findings may explain prior inconsistent evidence on EVT in patients with low NIHSS scores and underscore the need to individualize procedural thresholds in this population.
Glioblastoma Subtypes Exhibit Distinct Migration Mechanics and Immune Responses
Shamsan, Ghaidan A. , Liu, Chao J. , Braman, Brooke C. , Li, Ruyi , Rathe, Susan K. , Sarver, Aaron L. , Ghaderi, Nima , McMahon, Mariah , Klank, Rebecca L. , McFarren, S Joseph. , Masopust, David , Clark, H. Brent , Rosenfeld, Steven S. , Largaespada, David A. , Tschida, Barbara R , McFarren, S Joseph , Rosato, Pamela C , Masopust, David , Sarkaria, Jann N , Clark, H Brent , Rosenfeld, Steven S , Largaespada, David A. , Odde, David J , Shamsan, Ghaidan A , Liu, Chao J. , Rathe, Susan K. , Sarkaria, Jann N.

Mayo Clinic

Cancer Research Communications | July 14, 2026 | Volume: 6 | Issue: 8 | Pages: 1898-1915

10.1158/2767-9764.crc-25-0579 | PMID 42447444 Get It

Abstract Glioblastoma (GBM) remains a deadly cancer driven in part by invasion of tumor cells into the brain. Transcriptomic analyses have identified distinct molecular subtypes, but mechanistic differences that account for clinical differences are not clear. In this study, we show that, as predicted by the motor-clutch model of cell migration, mesenchymal glioma cells are more spread, generate larger traction forces, and migrate faster in brain tissue compared with proneural cells. Despite their rapid migration and comparable proliferation rates in vitro, mice with mesenchymal tumors survive longer than those with proneural tumors. This improved survival correlated with an immune response in mesenchymal tumors, including T cell–mediated. Consistently, inducing mesenchymal tumors in immunodeficient mice resulted in shorter survival, supporting a protective immune role in mesenchymal tumors. Thus, mesenchymal tumors have aggressive migration but are immunologically “hot,” which suppresses net proliferation. These two features counteract each other and may explain the lack of a strong survival difference between subtypes clinically, while also opening up new opportunities for subtype-specific therapies. Significance: This study highlights new mechanical and immunologic insights into GBM molecular subtypes using an integrated modeling–genome engineering strategy, which can potentially facilitate GBM subtype-specific therapeutic strategies.
SpaceXray: Feasibility and Diagnostic Capabilities of On-Orbit Medical Radiography
Gifford, Sheyna E. , Pohlen, Michael , Wang, Adam S. , Lerner, David J. , Wadhwa, Anna , Cairnie, Michael, Walter, Jeanne, Karim, Karim S. , Tilley, Steven , Karnick, Amol , Rosenberg, Marissa A , Petersen, Lonnie G , Gifford, Sheyna E. , Pohlen, Michael , Lerner, David J. , Wadhwa, Anna , Cairnie, Michael, Walter, Jeanne, Karim, Karim S. , Tilley, Steven

Mayo Clinic

Radiology | July 14, 2026 | Volume: 320 | Issue: 1 | Pages: No page available

10.1148/radiol.260258 | PMID 42446357 Get It

By acquiring the first human and equipment radiographs in space, this study demonstrated the feasibility of on-orbit radiography and expanded diagnostic capabilities for crew health and hardware evaluation.
Digital biomarkers in cardiovascular medicine: a scientific statement of the ESC Working Group on e-Cardiology, the ESC Working Group on Cardiovascular Pharmacotherapy, the European Heart Rhythm Association (EHRA) of the ESC, the Association for Acute Card
Corredoira, Pablo Manuel Fernández, Kaski, Juan Carlos, Duncker, David , Tubaro, Marco , Schuuring, Mark J. , Mamas, Mamas, Petersen, Steffen E, Kemps, Hareld M C, Locati, Emanuela T, Hill, Loreena, Keser, Nurgül , Verstrael, Axel , Friedman, P A, Casado-Arroyo, Rubén , Corredoira, Pablo M , Dörr, Marcus , Wilhelm, Matthias , Schuuring, Mark J , Mueller, Christian , Dilaveris, Polychronis E , Casado-Arroyo, Rubén , Duncker, David , Kaski, Juan Carlos , Wilhelm, Matthias , Petersen, Steffen E. , Vidal-Pérez, Rafael , Jensen, Magnus Thorsten , LUCIA, RAFFAELE DE , Hill, Loreena , Ramírez, Julia , Cluitmans, Matthijs J M , Friedman, Paul A.

Mayo Clinic

European Heart Journal - Digital Health | July 14, 2026 | Volume: 7 | Issue: 6 | Pages: No page available

10.1093/ehjdh/ztag074 | PMID 42491935 Get It

Abstract Cardiovascular disease is the leading cause of morbidity and mortality globally, imposing a substantial patient burden. Digital biomarkers derived from digital health technologies enable quantifiable, near-continuous, real-world capture of pathophysiological signals and are increasingly used across cardiovascular medicine. Their growth is often supported by big data analytics, artificial intelligence and connected sensors within the Internet of Things. This scientific statement systematically reviews digital biomarkers, their clinical utility across the cardiovascular care continuum, and summarizes major methodological and implementation challenges. We searched PubMed/MEDLINE, Embase and Scopus for phase III–IV cardiovascular trials published between 1 January 2019 and 1 August 2024 that collected digital biomarkers. We identified 541 records and included 32 trials (40 reports) enrolling 32 246 participants (44.71% women; mean age 66.2 ± 11.0 years). Heart failure was the most frequent target condition (16 trials, 50%), followed by cardiac implantable electronic devices trials (12 trials, 38%). Digital biomarkers included cardiac rhythm and heart rate, blood pressure, body weight, impedance-based measures, haemodynamic pressures, and physical activity and sleep patterns captured using diverse sensor technologies. Methodological quality was good (modal quality score 5; range 3–7), although most trials were unblinded. Current studies suggest potential clinical utility in selected cardiovascular conditions. Implementation remains challenging because of measurement variability, privacy and regulatory requirements, affordability and reimbursement barriers and inequities in access. Robust validation and outcome- and cost-effectiveness evidence are still needed. Registration number: CRD42024573879.
“Heart Sign” with Double Aortic Arch
Binder, Michael Scott , Majdalany, David , Majdalany, David S , Binder, Michael Scott

Mayo Clinic

Diagnostics | July 14, 2026 | Volume: 16 | Issue: 14 | Pages: 2188

10.3390/diagnostics16142188 | PMID 42510053 Get It

Double aortic arches are rare congenital malformations resulting from persistence of the right and left aortic arches, as opposed to normal regression of the left aortic arch. These vascular malformations can cause vascular rings since they encompass the trachea and esophagus, and lead to swallowing difficulties or respiratory difficulties from extrinsic compression. Typically, these are diagnosed in childhood but rarely may present in adults. In the presence of symptoms, which require formal gastrointestinal and pulmonary evaluation, surgical resection of the nondominant arch is typically recommended to release the vascular ring. Monitoring of the carotid and subclavian vasculature is performed intraoperatively to ensure distal perfusion is not affected following distal ligation of the arch.
Prospective Validation of the Movement Disorder Society Prodromal Multiple System Atrophy Criteria in Pure Autonomic Failure
Vernetti, Patricio Millar , Palma, Jose‐Alberto , Shibao, Cyndya A. , Freeman, Roy , Gibbons, Christopher H. , Singer, Wolfgang , Coon, Elizabeth A. , Miglis, Mitchell G. , Krismer, Florian , Fanciulli, Alessandra , Millar Vernetti, Patricio , Biaggioni, Italo , Shibao, Cyndya A , Freeman, Roy L. , Gibbons, Christopher , Singer, Wolfgang , Coon, Elizabeth Anne , Miglis, Mitchell G , Krismer, Florian , Fanciulli, Alessandra , Goldstein, David S. , Betensky, Rebecca A. , Kaufmann, Horacio , Palma, Jose-Alberto

Mayo Clinic

Movement Disorders | July 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/mds.70417 | PMID 42444112 Get It

Abstract Background The Movement Disorder Society (MDS) research criteria for possible prodromal multiple system atrophy (PP‐MSA) have not been prospectively validated. Objective To evaluate the diagnostic performance of the PP‐MSA criteria in a longitudinal cohort of patients with pure autonomic failure (PAF) and to assess whether additional clinical features improve their predictive value. Methods Seventy‐six patients with PAF enrolled across eight centers in the Natural History Study of the Synucleinopathies were followed for ≥6 years or until phenoconversion. Participants were classified according to MDS PP‐MSA criteria and followed for development of MSA, Parkinson's disease, or dementia with Lewy bodies. Diagnostic performance was assessed longitudinally. Analyses were repeated using a stricter olfactory threshold (University of Pennsylvania Smell Identification Test [UPSIT]≤28) as an exclusion criterion. Results Thirty‐eight participants met PP‐MSA criteria, of whom 12 phenoconverted to MSA within 6 years. Sensitivity was 100% at year 1 and 92% at year 6, whereas specificity ranged from 56% to 67%. Positive predictive value (PPV) ranged from 21% to 34%. Applying a stricter olfactory threshold improved specificity (90%–97%) and PPV (53%–83%), with a modest reduction in sensitivity (to 83%). Participants who phenoconverted to MSA were younger, had more severe urinary dysfunction, and greater orthostatic heart rate responses. Conclusions The PP‐MSA criteria demonstrate high sensitivity but limited specificity in patients with PAF. A stricter olfactory threshold improves diagnostic performance and may enhance cohort enrichment for clinical trials. © 2026 International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Drivers of Diagnostic Variation in a Digital Global Kidney Transplant Reader Study
Hofstraat-Boersma, Rianne, Long, Romy du , Buzzanca, Giorgio , Abiola, Adeyemi A., Albadri, Sam, Ali, Zahabia, Altaleb, Ahmed, Banu, Sultana G., Barry, Marc , Bhalodia, Ami , Bianco, Paola, Broecker, Verena , Buelow, Roman, Cheunsuchon, Boonyarit , Crisi, Giovanna M., Daneshvar, Simin, Dokouhaki, Pouneh, Drachenberg, C., Florquin, Sandrine, Gibson, Ian W., Gujarathi, Saurabh, Hendricks, Allen R. , Islam, Jaynul, Ismail, Wesam, Jagannathan, Geetha , Kläger, Johannes, Krizova, Adriana , Kurien, Anila A., Kwon, Boomi , Ledesma, Felipe L., Martin, Jonne, Mehta, Shweta S., Messias, Nidia , Mignano, Salvatore , Miranda, Monik E., Moeckel, Gilbert, Pala, Chiara, Ranson, Marc A., Rodriguez, A Castell, Rosenberg, Avi, Setty, Suman , Sheaff, M., Soares, Maria F.S., Surintrspanont, Jerasit , Terinte-Balcan, George, Testa, Francesca , Ticas, David O. Hendriquez, Toniolo, Maria F., Midden, Dominique van, Velagapudi, R, Viswanathan, Seethalakshmi , Stillfried, Saskia von, Kalverboer, Nienke , Bruns, Imke B. , Callegaro, Giulia , Vries, A A F De, Peters-Sengers, Hessel, Kers, Jesper, Hofstraat, Rianne , Adefidipe, Adeyemi Abiola, Albadri, Sam , Angioi, Andrea , Banu, Sultana Gulshana, Bianco, Paola, Buelow, Roman David, Chauveau, Bertrand , Chen, Guoli , Crisi, Giovanna Maria, Dendooven, Amélie , Drachenberg, Cinthia Beskow , Farris, Alton B. , Ferlicot, Sophie , Florquin, Sandrine , Fontana, Francesco , Gibier, Jean‐Baptiste , Gibson, Ian W. , Husain, Sufia , Ismail, Wesam, Kläger, Johannes Philipp , Kozakowski, Nicolas , Kurien, Anila Abraham , L’Imperio, Vincenzo , Ledesma, Felipe L , Low, Julia P. , Miranda, Monik Ediana , Price, Brendon , Ranson, Marc Andres, Roelofs, Joris J. T. H. , Sadeghipour, Alireza , Sekulic, Miroslav , Setty, Suman , Soares, Maria Fernanda , Terinte‐Balcan, George , Ticas, David Henriquez, Toniolo, María Fernanda , Midden, Dominique van , Velagapudi, Ramya Krishna , Stillfried, Saskia Freifrau von , Wu, Chih‐Ying , Water, Bob van de , Helm, Danny van der , Sengers, Hessel Peters , Kers, Jesper

Mayo Clinic

No container title available | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.09.26357318 Get It

ABSTRACT Background Diagnostic interpretation of kidney allograft biopsies using the Banff classification remains variable, but the determinants of this variability are not fully defined. We performed a global, fully digital multi-reader study to identify the principal drivers of disagreement in Banff-based assessment. Methods Thirty-six kidney transplant biopsies were independently scored by 67 renal pathologists on a standardized digital platform. Readers assessed Banff lesions on hematoxylin and eosin, periodic acid–Schiff, and Jones’ silver stains; final diagnostic categories were assigned using prespecified Banff-based decision rules. Interobserver agreement was quantified with Gwet’s agreement coefficient (AC) statistics. Determinants of diagnostic agreement were evaluated using pairwise mixed-effects logistic regression, and reader similarity was examined by principal component analysis (PCA) with post hoc molecular annotation. Results Agreement for final diagnostic categories was moderate (Gwet’s AC1, 0.55; 95% CI, 0.47–0.63). Lesion-level agreement varied substantially, with lowest agreement for selected threshold-dependent inflammatory or semi-quantitative lesions, including interstitial inflammation in areas of IFTA, peritubular capillaritis and arteriolar hyalinosis. Diagnostic concordance differed markedly across biopsies, indicating strong case-level heterogeneity. In pairwise models, differences in active inflammatory and vascular lesion scoring were the strongest correlates of diagnostic disagreement; reader experience and geography contributed minimally. Principal component analysis showed reader variation was organized along two dominant axes: a rejection-calling threshold axis linked mainly to tubulointerstitial inflammatory injury, and a T cell-mediated (TCMR/TI) and antibody-mediated/microvascular (AMR/MVI) inflammation-oriented phenotypic classification axis. Conclusion Interobserver variation in Banff-based kidney transplant biopsy assessment is structured rather than random and driven mainly by how readers threshold and integrate key inflammatory lesion compartments rather than experience or geographic location.
Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease
Soleimani‐Meigooni, David N. , Chiotis, Konstantinos, Allen, Isabel E., Rabinovici, Gil D., Joie, Renaud La , Group, Meta-Centiloid Study, Apostolova, Liana G. , Asken, Breton M., Benzinger, Th., Betthauser, Tobey J., Bluma, Marina, Bombois, Stephanie, Bourgeat, Pierrick, Bouteloup, Vincent , Braskie, Meredith N., Brendel, Matthias, Brickman, Adam M., Bryant, Natalie, Bullich, Santiago , Carrillo, Maria C., Casaletto, Kaitlin, Cash, David M., Chang, Chiung-Chih, CHANG, H L, Chao, Yishu , Collij, Lyduine E., Corrada, Maria M., Craft, Suzanne , Dickerson, Bradford C., Dubois, Bruno, Dufouil, Carole, Fajardo, Alfonso, Farrar, Gill , Fortea, Juan, Frings, Lars , Frisoni, Giovanni B., Gardner, Raquel C., Gnörich, Johannes , Gordon, Brian A., Gu, Yuna , Guan, Yihui, Guo, Tengfei, Hanseeuw, Bernard J., Hansson, Oskar, Harrison, Theresa M., Huang, Qi, Huang, ST , Iaccarino, Leonardo, Ishii, Kazunari, Ishi, Kenji, Jagust, William J., Johnson, Sterling C., Kato, Takashi, Katsumi, Yuta, Kaye, Jeffrey, Kolinger, Guilherme D., Kramer, Joel H. , Landau, Susan M., Landeau, Brigitte, Lao, Patrick J., Lee, Sangwon, Lopresti, Brian J., Lowe, Val J. , Luchsinger, José A., Mao, Xiaoxie, March, Andrew, Masters, Colin L., Meyer, Philipp T., Mezenge, Florence, Mormino, Elizabeth C., Franquesa‐Mullerat, María , Nakamura, Akinori, Nordberg, Agneta, O’Brien, John T., O’Bryant, Sid E., Pappas, Ioannis, Peretti, Debora E., Rowe, Christopher C., Rowe, James B., Schwartz, Daniel L., Seo, Sang Won , Shekari, Mahnaz, Smith, Ruben, Snyder, Heather M. , Sokolowski, Andrzej, Sperling, Reisa A., Sun, Pan, Taggett, Jacinda Z., Touroutoglou, Alexandra , Vaillancourt, David E., Giessen, Elsmarieke van de, Vijverberg, Jort, Villemagne, Victor L. , Villeneuve, Sylvia , Wang, Wei-en, Weiner, Michael, Woodworth, Davis, Xiao, Cally , Xie, F, Yoon, Yeojun, Yun, Mijin, Severanc, A4, ABIDE, ADNI*, ADNI-DoD, AgeWell, AIBL, AMYPAD, BACS, BATON, BIOCARD, BLSA, BioFINDER-2, BrANCH, CPAS, DETECT-AD, GEMS, GHABS, HABS, HABS-HD, IDEAS, IMAP, INSIGHT-preAD, Insight46, K-ROAD, LEADS, MCSA, MULNIAD, MEMENTO, SCAN, PREVENT-AD, SPIN,, Corrada, María M. , La Joie, Renaud , Blazhenets, Ganna , Chiotis, Konstantinos , Allen, Isabel Elaine , Rabinovici, Gil D. , Asken, Breton M. , Bejanin, Alexandre , Benzinger, Tammie L.S. , Betthauser, Tobey J. , Blūma, Marina , Bombois, Stéphanie , Bourgeat, Pierrick , Braskie, Meredith N. , Brendel, Matthias , Brickman, Adam M. , Carrillo, María C. , Casaletto, Kaitlin B. , Cash, David M. , Chang, Chiung‐Chih , Chang, Hsin‐I , Chêne, Geneviève , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Bradford Clark , Dubois, Bruno , Dufouil, Carole , Fortea, Juan , Garibotto, Valentina , Gordon, Brian A. , Guan, Yihui , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Iaccarino, Leonardo , Ishii, Kazunari , Ishii, Kenji, Jagust, William J. , Johnson, Sterling C. , Katsumi, Yuta , Kaye, Jeffrey , Koeppe, Robert A. , Kolinger, Guilherme Domingues , Landau, Susan , Landeau, Brigitte , Lao, Patrick , Lee, Sangwon, Lleó, Alberto , Lopresti, Brian J. , Malpetti, Maura , March, Andrew, Masters, Colin L. , Mézenge, Florence, Mormino, Elizabeth C. , Nakamura, Akinori , Nordberg, Agneta , O'Brien, John Tiernan , O’Bryant, Sid E. , Pappas, Ioannis , Quenon, Lisa , Rowe, Christopher Cleon , Rowe, James B. , Rudolph, Marc D. , Salvadó, Gemma , Schott, Jonathan M. , Schwarz, Christopher G. , Shekari, Mahnaz , Silbert, Lisa C. , Smith, Ruben, Sokolowski, Andrzej, Sperling, Reisa Anne , Sun, Pan , Taggett, Jacinda , Toga, Arthur W. , Vaillancourt, David E. , Giessen, Elsmarieke van de , Vemuri, Prashanthi , Villain, Nicolas , Wang, Wei‐en , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Yun, M R

Mayo Clinic

JAMA | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.13116 | PMID 42441390 Get It

Importance Amyloid positron emission tomography (PET) is increasingly used in research and clinical settings to determine the etiology of cognitive decline and eligibility for amyloid-targeting therapies. To assist with amyloid PET evaluation and to guide clinical decision-making, images can be quantified in a standardized unit called Centiloid, the interpretation of which can vary according to the method and threshold used. Objective To collect Centiloid values from available studies and determine robust positivity cutoffs using data-driven methods and correspondence with visual reads. Data Sources PubMed search (October 2024) identified studies with Centiloid values. Corresponding authors were invited to share individual participant data. Additional data were obtained through access-controlled repositories and conference outreach (July 2024-July 2025). Study Selection Studies were included if they provided Centiloids, radiotracer, age, and sex. Data Extraction and Synthesis Each study was analyzed using a unified statistical pipeline; study estimates were pooled using random-effects meta-analysis. Main Outcomes and Measures Gaussian mixture models (GMMs) were fitted to Centiloid values for each study. In studies with a bimodal distribution (per integrated completed likelihood), single cutoffs for positivity were set as mean plus 2 SDs of the lower gaussian component. Using GMMs, a double-cutoff approach defined a lower certainty range using a 90% posterior probability cutoff for assignment to the low (amyloid-negative) vs high (amyloid-positive) component. An alternative Centiloid cutoff was derived from maximizing the correspondence (Cohen κ) with the binary visual reads when available. Results This meta-analysis included cross-sectional amyloid PET scans acquired with 5 radiotracers from 49 227 participants across 53 studies from 15 countries (mean age, 71 years; 54% female, 62% cognitively impaired). The data-driven GMM approach identified a bimodal distribution in 51 studies (n = 48 786), resulting in a single cutoff for positivity of 18 Centiloids (95% CI,16-19; I 2 = 97%). The double-cutoff approach revealed high confidence for interpreting scans as negative when Centiloid values were lower than 11 (95% CI, 9-13; I 2 = 95%) and interpreting scans as positive if Centiloid values were higher than 26 (95% CI, 24-28; I 2 = 95%). In analyses of correspondence with binary (positive or negative) visual reads of amyloid PET scans (n = 35 045; 36 studies), Centiloids were highly predictive of visual positivity (Cohen κ, 0.86; 95% CI, 0.83-0.89; I 2 = 96%) with a cutoff of 27 Centiloids (95% CI, 24-30; I 2 = 80%). Conclusions and Relevance In this individual participant data meta-analysis, positivity cutoffs converged around 18 Centiloids (data-driven) and 27 Centiloids (visual reads). Findings from a double-cutoff analysis suggest that scans in the 11 to 26 Centiloid range should be interpreted with caution depending on the context of use.
Plasma Phosphorylated Tau 217 in Participants at Risk for Chronic Traumatic Encephalopathy
Miner, A, Zetterberg, Henrik, Blennow, Kaj, Groh, Jenna R., Singh, Alpana, Dieckhoff, Kari, Tripodis, Yorghos, Adler, Charles H., Balcer, Laura J. , Bernick, C L, Peskind, Elaine, Asken, Breton M., Tanner, Jeremy A., Rabinovici, Gil D., Banks, Sarah J., Barr, William B., Wethe, Jennifer V., Cantu, Robert C., Dodick, David W., Mez, Jesse, Palmisano, J, Martin, Brett, Stein, Thor D., McKee, Ann C., Cummings, Jeffrey L., Shenton, Martha E., Reiman, E Bieto, Rc, Stern, Ashton, Nicholas J., Alosco, Michael L., Chen, Kewei, Protas, Hillary, Su, Yi, Boker, Connie, Au, Rhoda, Farrer, Lindsay, Helm, Robert, Kowall, Neil, Mercier, Gustavo, Otis, James, Weller, Jason, Bragg, Tahlia, Simkin, Irene, Trujillo-Rodriguez, Diana, Amerongen, Suzan van , Andino, Alondra, Conneely, Shannon, Diamond, Courtney, Fagle, Tessa, Haller, Olivia, Hunt, Tennyson, Gullotti, Nicole, Kossow, Bailey, Kugelmass, Carrie, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen, Nanna, Mary, DiPopolo, Marty, Platt, Taylor, Rice, Fiona, Sestak, Madison, McClean, Michael, Annis, Douglas, Chaisson, Christine, Dixon, Diane, Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Lu, Jun, Ojo, E O, Pine, Brittany, Ramachandran, Janani, Baucom, Zachary, Tuz‐Zahra, Fatima , Yhang, Eukyung , Bouix, Sylvain, Fitzsimmons, Jennifer, Lin, Alexander P., Koerte, Inga K., Pasternak, Ofer, Arciniega, Hector , Billah, Tashrif , Bonke, Elena, Breedlove, Katherine M. , Carrington, Holly, Coello, Eduardo , Coleman, Michael J., John, Omar , Jung, Leonard, Liao, Huijun, Loy, Maria, Rizzoni, Elizabeth, Schulz, V. D., Silva, Annelise, Vessey, Brynn, Wiegand, Tim L.T, Miller, Jason, Ritter, Aaron , Sabbagh, Marwan, Cruz, Raelynn de la, Durant, Jan, Golceker, Morgan, Harmon, Nicolette, Kaylegian, Jaeson, Long, Rachelle, Nance, Christine, Sandoval, Priscilla, Staples, Miranda, Clark, Emma F., Serrano, Andrew, Geda, Yonas, Duffy, Amy, Falk, Bryce, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Bellgowan, Patrick, GOLDBERG, JUDITH, Joseph, Binu , Kirov, Ivan, Lui, Yvonne, Marmar, Charles, Wisniewski, T R, Al-Kharafi, Alhassan, George, Allan, Hasanaj, Lisena, Martin, Sammie, Riley, Edward, Runge, William, Serrano, Liliana , Iliff, Jeffrey, Li, Gail, Janssen, D, Meabon, James, Piantino, Juan, Schindler, Abigail, Thomas, Ronald, Colasurdo, Elizabeth , Shofer, Jane, Marcus, Daniel S., Gurney, Jenny , Greenwald, Richard, Johnson, Keith A., Singh, Alpana , Singh, Alpana , Miner, Annalise E., Zetterberg, Henrik , Blennow, Kaj , Groh, Jenna R. , Singh, Alpana, Tripodis, Yorghos , Adler, Charles H. , Bernick, Charles , Peskind, Elaine R. , Asken, Breton M. , Rabinovici, Gil D. , Banks, Sarah J. , Barr, William , Wethe, Jennifer V. , Cantu, Robert C. , Dodick, David W. , Mez, Jesse , Stein, Thor D. , McKee, Ann C. , Cummings, Jeffrey L. , Shenton, Martha E. , Reiman, Eric M. , Ashton, Nicholas J. , Alosco, Michael L. , Protas, Hillary , Au, Rhoda, Weller, Jason , Trujillo‐Rodriguez, Diana , Fagle, Tessa, Mariani, Megan, McLaughlin, Kathleen , Pulukuri, Surya Vamsi , Sestak, Madison, McClean, Michael D , Annis, Douglas, Finney, Carolyn, Lu, Jun, Pine, Brittany, Ramachandran, Janani , Baucom, Zachary, Bouix, Sylvain , Koerte, Inga K , Pasternak, Ofer , Bonke, Elena M. , Carrington, Holly , Coleman, Michael J. , Liao, Huijun, Schulz, Vivian, Wiegand, Tim L. T. , II, Robert W. Turner , Marek, Kenneth , Geda, Yonas E. , Howard, Marci, Montague, Michelle, Babcock, Debra, Bellgowan, Patrick S.F. , Kirov, Ivan, George, Allan, Meabon, James S. , Piantino, Juan , Thomas, Ronald G. , Colasurdo, Elizabeth A. , Shofer, Jane, Marcus, Daniel S., Johnson, Keith A.

Mayo Clinic

JAMA Network Open | July 13, 2026 | Volume: 9 | Issue: 7 | Pages: e2622966

10.1001/jamanetworkopen.2026.22966 | PMID 42440317 Get It

Importance In vivo biomarkers for detecting neuropathologies from repetitive head impacts (RHI), including chronic traumatic encephalopathy (CTE), are needed. Objective To evaluate the utility of plasma phosphorylated tau 217 (p-tau217), assess its performance as a beta-amyloid (Aβ) biomarker in participants with RHI exposure at risk for CTE, and explore concordance with CTE neuropathology in a postmortem subsample. Design, Setting, and Participants This longitudinal, multicenter, case-control study used data from the Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of CTE (DIAGNOSE CTE) Research Project, collected from September 2016 to October 2023. Participants were former American football players (case participants) and asymptomatic men unexposed to RHI (control participants). A subsample had available neuropathologic data. Exposures RHI, traumatic encephalopathy syndrome (TES) diagnoses, and levels of CTE certainty. Main Outcomes and Measures Plasma p-tau217 (classified as positive [≥0.63 pg/mL], intermediate [0.40-0.62 pg/mL], and negative [&amp;lt;0.40 pg/mL]), Aβ–positron emission tomography (PET; 18 F-florbetapir; with Aβ-positive defined as a standardized uptake value ratio [SUVR] ≥1.10), and tau-PET ( 18 F-flortaucipir). TES diagnoses were assigned by multidisciplinary consensus conference. Analyses of postmortem brains controlled for age, race, and APOE ε4 status. Results Among 231 participants (mean [SD] age, 57.75 [8.25] years), 177 were former football players (117 professional and 60 college) and 54 were unexposed participants. Former football players had higher baseline mean (SD) p-tau217 concentrations than unexposed participants (0.35 [0.26] pg/mL vs 0.27 [0.14] pg/mL; P = .008), although this was driven by a higher proportion of Aβ-PET–positive participants among former players. Plasma p-tau217 increased over time across the sample (B = 0.207 [95% CI, 0.117-0.298]; P &amp;lt; .001), with no significant time × exposure group interactions. Among football players, p-tau217 showed no time × group interactions with TES diagnosis, TES-CTE certainty, or RHI metrics. Higher p-tau217 concentration correlated with higher global Aβ-PET SUVR (B = 0.058 [95% CI, 0.053-3.501; P = .01), with a few discordant cases (5 participants were p-tau217–negative and Aβ-PET–positive; 7 participants were p-tau217–positive and Aβ-PET–negative). P-tau217 had similar areas under the curve for projecting Aβ-PET positivity as cerebrospinal fluid (CSF) p-tau181/Aβ42 and CSF Aβ40/42 measures (p-tau217: AUC, 0.88 [95% CI, 0.80-0.96]; CSF p-tau181/Aβ42: AUC, 0.89 [95% CI, 0.79-1.00]; CSF Aβ40/42: AUC, 0.85 [95% CI, 0.72-0.98]). Among 9 brain donors, 6 had CTE (stages II-IV; none with Alzheimer disease). Seven had negative or intermediate p-tau217, concordant with Aβ-PET. Two p-tau217 outliers with stage III CTE had normal concentrations upon additional testing. Conclusions and Relevance The findings of this study suggest that plasma p-tau217 concentration is unlikely to be useful for the detection of CTE, but it does show utility for ruling out Aβ pathology in participants at risk for CTE.